Beijing Abace Biology Co., Ltd. v. Zhang

122 F.4th 448
Court of Appeals for the First Circuit·Decided December 2, 2024·No. 24-1424·Published·Cited by 1 cases

Opinion

United States Court of Appeals For the First Circuit

No. 24-1424 BEIJING ABACE BIOLOGY CO., LTD., Plaintiff, Appellant,

v.

CHUNHONG ZHANG and MTOZ BIOLABS, INC., Defendants, Appellees.

APPEAL FROM THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS

[Hon. Indira Talwani, U.S. District Judge]

Before

Rikelman, Selya, and Kayatta, Circuit Judges.

Willard C. Shih, with whom Stephen T. Melnick, Littler Mendelson, P.C., and Wilentz, Goldman & Spitzer P.A. were on brief, for appellant.

Zackary L. Stillings, with whom Yuanyou Sunny Yang and Frost Brown Todd, LLP were on brief, for appellees.

December 2, 2024

SELYA, Circuit Judge. Plaintiff-appellant Beijing Abace Biology Co., Ltd. (Abace) challenges the district court's entry of summary judgment in favor of defendants-appellees Dr. Chunhong Zhang (Dr. Zhang) and MtoZ Biolabs, Inc. (MtoZ). Discerning no error, we affirm.

I

We rehearse the relevant facts and travel of the case.

In that endeavor, we "scrutinize the record in the light most favorable to the summary judgment loser and draw all reasonable inferences therefrom to that party's behoof." All. of Auto. Mfrs. v. Gwadosky, 430 F.3d 30, 34 (1st Cir. 2005).

Abace and Creative Dynamics, Inc. (Creative Dynamics)

are affiliated companies that provide research and development resources in the life sciences and pharmaceutical spaces. Both companies were founded in 2004. Abace is headquartered in Beijing and Creative Dynamics is headquartered in New York. Although the precise nature of the corporate relationship between Abace and Creative Dynamics is murky, the record suggests that the two firms have a "contract" relationship and that some corporate officers work for both companies.1 In December of 2014, Abace hired Dr. Zhang. She became a "supplier" in its creative proteomics department. As such, Dr.

1 We need not probe this too deeply as only Abace — and not Creative Dynamics — is a party to this appeal.

Zhang was required to "find the product or service" requested by "go[ing] online, like Google or Baidu [a Chinese search engine], and search[ing] which company can provide this [product or service] and then call[ing] them to ask them for the price and how long they can deliver this [product or service] and then giv[ing] the supplier's price back to [sic] sales person." While working for Abace, Dr. Zhang was stationed in China.

During her tenure with Abace, Dr. Zhang signed several employment-related agreements. These included two so-called Cadres Agreements, dated January 9, 2016, and November 2, 2016, respectively.2 The agreements are the same in all aspects relevant to this decision. Separate and apart from the Cadres Agreements, the record reflects that the parties entered into a Confidentiality and Non-Competition Agreement (the Non-Compete Agreement) and a Labor Contract, both dated November 2, 2016.

Each of the Cadres Agreements stated that it "appli[ed]

to all current employees of Creative Dynamics and CD Biosciences (CD Inc), i.e., all current employees of the Company." We assume — favorably to Abace — that Dr. Zhang fell within the reach of those agreements.

2 Although these are called the "Creative Dynamics Cadres Agreements," the signatories are Abace and Dr. Zhang. This discrepancy is unexplained, but it is not material to the resolution of this appeal.

Those agreements also defined certain terms. As relevant here, those agreements defined "senior cadre[s]" as "the first and second level leaders of each Division," meaning the "primary and secondary head of each Division." Additionally, they defined "senior executive[s]" as those persons who "[e]xercise the right of operation and management" and who have certain powers over personnel. What is more, the January Cadres Agreement stated that, "[w]ithin 2 years from the date of termination of senior executives, they shall not hold a position or hold a part-time job in an organization with similar business and competitive relationship with the Company."

On May 1, 2017, Dr. Zhang's employment with Abace was terminated, and she signed an employment separation certificate. This certificate referred to the obligations in the Non-Compete Agreement.

In September of 2017, Dr. Zhang co-founded MtoZ, a company headquartered in Massachusetts. MtoZ provides proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers. See About Us, MtoZ-Biolabs, https://www.mtoz-biolabs.com/about-us.html [https://perma.cc/5SJQ-4NCF].

Abace responded to this initiative by filing an action against Dr. Zhang and MtoZ in the United States District Court for

the District of Massachusetts.3 In the operative pleading (the second amended complaint), it claimed that Dr. Zhang had breached both her contract with Abace and her fiduciary duty to Abace; that MtoZ had tortiously interfered with Abace's business and business relationships; and that Dr. Zhang and MtoZ were liable for unjust enrichment.4 After pretrial discovery was completed, all parties moved for summary judgment. The district court granted summary judgment in favor of Dr. Zhang and MtoZ. See Creative Dynamics, Inc. v. Zhang, No. 20-11711, 2024 WL 1375941 (D. Mass. Mar. 31, 2024). This timely appeal followed.

II

Summary judgment is appropriate when "the movant shows that there is no genuine dispute as to any material fact and the movant is entitled to judgment as a matter of law." Fed. R. Civ. P. 56(a). A dispute is genuine if "the evidence about the fact is such that a reasonable jury could resolve the point in favor of the nonmoving party." Rivera-Muriente v. Agosto-Alicea, 959 F.2d 349, 352 (1st Cir. 1992) (quoting United States v. Plat 20, Lot 17, Great Harbor Neck, 960 F.2d 200, 204 (1st Cir. 1992)). A fact

3 There were additional parties below (including Creative Dynamics, as a plaintiff). None of these parties is a party to this appeal.

4 Simultaneously, Abace sought relief against Dr. Zhang in

China in both arbitration and court proceedings. Neither of those proceedings is still pending, and we make no further mention of them.

is material if it could affect the outcome of the case. See Baker v. St. Paul Travelers Ins. Co., 670 F.3d 119, 125 (1st Cir. 2012). "The summary judgment ritual is standard fare: once the movant 'adumbrate[s] an absence of evidence to support the nonmoving party's case,' . . . the burden shifts to the nonmovant to establish the existence of a genuine issue of material fact." Boykin v. Genzyme Therapeutic Prods., LP, 93 F.4th 56, 60 (1st Cir. 2024) (alteration in original) (quoting Brennan v. Hendrigan, 888 F.2d 189, 191 (1st Cir. 1989)).

We review the district court's grant of summary judgment de novo. See Spencer v. Roche, 659 F.3d 142, 145 (1st Cir. 2011). We peruse the record in the light most hospitable to the nonmovant of the granted motion and draw all reasonable inferences in the nonmovant's favor. See id.

III

This case arises under the aegis of diversity jurisdiction. See 28 U.S.C. § 1332(a). The parties agree that the substantive law of China controls. The district court accepted this agreement, and so do we. See Borden v. Paul Revere Life Ins. Co., 935 F.2d 370, 375 (1st Cir. 1991) ("Where . . . the parties have agreed about what law governs, a federal court sitting in diversity is free, if it chooses, to forgo independent analysis and accept the parties' agreement.").

Free access — add to your briefcase to read the full text and ask questions with AI

Beijing Abace Biology Co., Ltd. v. Zhang, 122 F.4th 448 (1st Cir. 2024).

122 F.4th 448 (Beijing Abace Biology Co., Ltd. v. Zhang) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related